Xinwen Biotech Closes ￥10 Million Angel Financing

(VCBeat) July. 13, 2021 -- Recently, Jiaxing Xinwen Biotechnology Co., Ltd. ("Xinwen Biotech") recently closed tens of millions in the angel financing round, with participation from Enshe Joint Family Office and the listed company Yongguan Adhesive Products (stock code: 603681). This round of financing will be used for the industrialization of transdermal preparations in the field of medical cosmetology and the clinical R&D of innovative transdermal preparations in pain management, neurology, and other fields.

With modern transdermal technology as the core, Xinwen Biotech is committed to the research, development, production, sales, and cooperative development of new transdermal medicines and health products with innovative and clinical advantages in the fields of pain management, neurology, medical cosmetology, and health management.

The founder, Dr. Xin Zhang, was the Chief Technology Officer of ALZA, a pioneer in modern transdermal drug delivery technology, and the Global Director of the Chemical Division of Johnson & Johnson. The founding members of the company all have more than 20 years of R&D and management experience in the transdermal drug delivery industry. Its technical and management team has a mature technology reserve of transdermal drug delivery and has successfully developed and industrialized a number of innovative transdermal preparations at home and abroad.

Transdermal drug delivery refers to the absorption of drugs from the skin into the blood circulation of the whole body to achieve effective blood concentration, for the clinically approved purpose of disease treatment or prevention. Transdermal administration has the following advantages over oral and injection:

1) Avoid the first-pass effect, reduce gastrointestinal side effects and improve bioavailability;

2) Stable dose and longer duration of administration;

3) For children, the elderly, pregnant women and other special groups of people, convenient drug administration can increase the medical compliance of patients.

Founded in 2019, Enshe Joint Family Office is one of the first family offices in China that focus on life science and healthcare. Since its establishment, Enshe Joint Family Office has been committed to providing family health management, industrial investment and life technology services to private groups and families in China. Enshe Joint Family Office has a dedicated investment team and a medical group to fully support private entrepreneurs.

As a large-scale high-tech enterprise integrating production, research and sales, Yongguan Adhesive Products specializes in the production of various adhesive products. The company was listed on the Shanghai Main Board on March 26, 2019, stock code: 603681. The company now has two production bases, one is located in Zhujiajiao Industrial Park, Qingpu District, Shanghai and another is located in Yuanshangang Industrial Park, Dongxiang District, Fuzhou City, Jiangxi Province, covering a total area of more than 40,000 square meters.